Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OCGN looks great here. Would like to see more volume.
No offense, lol, but any experience you have had in scammy companies with no reputable people involved, no worldwide rights from NIH, no licenses from other companies etc does not apply here.
If an attorney wants to give an illegal Legal Opinion...and get fined or disbarred...you are correct.
But, like everything in Business, if you do business legally, insiders will not get a legal opinion to lift the Restricted legend off the certificate. AND the brokerage firm's legal dept double checks that legal opinion before permitting a sale.
In other words, unless you believe that insiders are really not interested in building the business, are using an unethical attorney for the legal opinion, use a sloppy Transfer Agent that does not chech out certificate requests and use a brokerage firm that does not verify a legal opinion, there is NO way that insiders can sell.
Prove to me that insiders cannot steal. Prove it in the bylaws.
Unbelievable.
Do you have any idea what the process is to sell stock? I am not being sarcastic.
Do you know what a Transfer agent does? What a legal opinion requirement is?
What the legal department at a brokerage firm does when they receive share certificates?
Please answer each of the above.
Anything that can increase the longevity of the current vaccines or help immuno-compromised patients that cannot take the current vaccines would be beneficial and of interest to the government.
Here you go with the information
https://www.sec.gov/reportspubs/investor-publications/investorpubsrule144htm.html
With more capital, you would think they have the funds to invest in more crypto miners machines. Ethereum prices are going up too.
Lots of news here. Why no volume?
That move would be dependent upon creat clinical trial results
There is no irrefutable evidence of insider trading. No filings of selling by insiders as required. A tweet that shows an increase in the float definitely does not mean insiders selling with no filing disclosures.
You can have an increase in the float if restricted shares from the prior company get the Restricted legend removed after getting a legal opinion.
Sorry, but if you start accepting illegal actions as possible, you never would invest in a small company.
Insiders cannot sell their shares yet. And cannot for at least another year.
And, No, I will not repeat my prior posts that explained what any investor should know about restrictions on insiders and affiliate stock and the disclosure eequirements
Alert to New Investors
There has been false info offered here regarding whether or not insiders can begin selling shares this month.
They cannot begin selling shares until 12 months AFTER the company files audited financials (designated as currently reporting).
And once these 12 months are up, then selling can only be at 1 percent of shares outstanding every 90 days.
End of Story
Please disregard the false info regardless how often it is repeated
Shorts do take advantage of upside moves to get a higher SHORT price so they can walk it down again. These small companies cannot keep up with the news flow that will keep getting new investors.
BUT--if the company can surprise investors AND the shorts with unexpected positive news--that iswhen i gets fun.
Squeeeezzzee!
In the past, I have done very well by averaging in at lower prices at the end of a year when tax loss selling hits because buyers back off because they know there will be more exposure to more tax loss selling. Which makes the price weaker than if it was earlier in the year with the same circumstances (little news, possible RS etc.).
I have done well by just doing DD on stocks hitting 52 week lows to see if there is some legit reason that the stock has headed lower--like a failed clinical trial, horrible earnings, CEO suddenly resigning etc. Then buying some shares to sell in January (the famous January Effect) after the last day of taking a capital loss happens--end of Dec.
No one is selling stock on January to take a tax loss. Which is why weak stocks can do very well in January.
CUBT needs to mess with the best laid plans of tax loss sellers by getting any legitimate news out ASAP. Not made up news (which they wisely not done in the past), but something on clinical trial start dates, CRO (clinical research organization), partnership, etc.
GL to everyone. If I am wrong about CUBT, the laughs will be at my expense. But I believe I will be doing very well over the next few weeks--into January.
Looks like a Buy on Rumor, Sell on News deal here.
Apparently we are seeing some tax loss selling now--which is why we saw stupid low prices today. When you are trying to book a capital loss, you just sell and if a lower prices comes up in your trade that you did not expect, you get a bigger loss.
There is no getting around the fact that a possible RS scares many into just selling out. Those who are booking a loss now have to wait 30 days before they get back in (assuming they care to get back in) o be able to book the loss (Wash Sale Rule).
If there is no substantive news that comes out before those 30 days are up,
the sellers probably can get in with their loss booked, and maybe not getting in at a much higher price.
But if there is something that comes out before Dec 7--the higher prices to be had may be much higher.
Either way, I would think that the CEO would post on his blog within that time frame (at the minimum).
Or, a Press Release--maybe a Letter to Shareholders PR.
They have to file their 10-Q in the by November 15. Mayber right after they file.
GLTA
At what point does the supply chain problems affect crypto miners ordering more machines?
Company I work for closed their offices and is now totally virtual. There was an assessment that redirecting all the costs associated with an office---rent, utilities, insurance, janitorial services etc.--- to doing the work. Outsourcing certain necessary jobs helped the bottom line.
Minimizing payroll and fixed costs seems wise to me.
What sort of news are you expecting to move OCGN higher?
Idaho Reports First Human to Die From Rabies Since 1978
Saw it on Fox News
Healthy distributions and prospects for capital appreciation is not a bad combo
Incorrect.
From PR last year on PRV
"Rabies is one of only 14 diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria.
Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance. Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged, and their value has increased. In 2016–2018, the value of a voucher ranged from $125 million to $200 million."
Separately:
The highest price paid for a priority review is $350 million in August 2015, when United Therapeutics sold its voucher to AbbVie.
And in May 2015 Retrophin sold a PRV, originally transferred from Asklepion Pharma, to Sanofi for $245 million.
Based on the data available to GAO, 17 of the awarded PRVs were subsequently sold to another drug sponsor. The prices for 14 of the 17 transferred PRVs were available, and ranged from $67.5 million for one sold in fiscal year (“FY”) 2014 to $350 million for one sold in FY 2015. The reported range has narrowed considerably for those sold since February 2017 to $80 to $130 million.
From the FDA
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/tropical-disease-priority-review-voucher-program
No denying the 18 month chart here.
The Company will most likely clarify things about potential PRV's. My reading of the PR from last year is that PRV's can be issued for an orphan drug entering clinical trials for an unmet need. No alternative effective therapy available.
PRV's have changed hands--been purchased- by companies wanting a PRV for their own drug. The highest PRV valuation and purchase to date was $300 million (probably an outlier).
Probably best that we wait for news from the company instead of eating our young.
Could be a strong opening on Monday. Hope it does not gap.
Wise move. The chart needs to consolidate and establish a higher base.
Sad to see that there are "investors" who do not know the how small biotechs boot strap their way to building a business. Because they cannot afford to bring professionals on to the payroll, they recruit people that can advance the business plan with their only compensation being RESTRICTED stock that will not be worth anything significant unless they can assist the company in being successful.
They still have their regular jobs in the industry, but they can advise, introduce, streamline, plan etc. on the side.
Now, if you are assuming someone --a professional with a reputation-- will join, add the affiliation to CUBT to their resume and then,do nothing just so others work to make the stock worth something, you may have a point.
Less time spent kevetching and more time doing due diligence on a company that you really want to be in would be advisable.
Do not worry about FOMO. No one here will tell you if things went well.
I never hold on with my entire position if any stock spikes on huge volume unless there is big news to justify a longer move up.
OCGN's RSI on he charts was over 70--classic indicator to start taking chips off the table.
So you got out?
Flipped out of that one nicely.
May get in later.
I agree that crypto miners that have the capital to expand will be the winners. Just do not overpay and be willing to take profits if the Reddit guys start up.
Agreed on big news is necessary...otherwise this little circle jerk here will not attract fresh investment. And something tells me that management know more than we do in what is coming up and what is necessary to move forward.
Good to see that those with zero holdings still have questions and advice for mgmt.
Hope this is not one of those but in rumor, sell on news.
Nice call
OLB really took off today
Doesn't the chart show that the stock is up big-time over the past 18 months,hobo?
Thank you for those shares at .075. Seriously. Never thought I would get a chance for 75,000 more at that price. Already up over 10 percent.
You are out of your mind, lizard. I bet we see .25 before any reverse is announced. Pretending to have all the facts should not be mistaken for informed expertise.
Any Positive development announced is not going to result in more selling by new buyers. Sorry, but 25 years of trading stocks, including microcaps, will not permit me to see inaccurate info to go without comment.
You have an opinion. And my informed opinion is that you are wrong.
G'day
Great momentum here. Any shorts have to be worried.
3F-- sometimes you wonder if we think about ourselves so much that we forget that if the stock went higher because the insiders had NOT converted, the eventual conversion would have hurt NEW investors getting in at, say, .25 to.35. Would that have been fair to them?
You, having bought in at $-.007 could have sold all along the way to .35--but someone would have been buying in at higher prices. Good for you and me, but bad for the newbies.
This potential RS, IMO, is for something in the works for an up listing. Not just incessant dilution with no progress on the core business. There is no perfect time to do the RIGHT thing and inform shareholders and potential new investors that a RS is being considered. But when if and when a RS is announced, I bet it is in tandem with REAL significant news and a NASDAQ or higher listing. Better to not hur newbies at higher prices--take he hit now. But they are now done everything necessary for the next step--up listing and/or partnership announcement from a partner that does no twant a partner on the OTC.
The NIH would be knocking on their door for that worldwide patent if they did nothing with it. And I would be shocked if that was there long term goal.
In the interest of not appearing to be a Polyanna, I think this Notice o Shareholders was mishandled somewhere. It is not far that some investors were informed of a possibility of a RS so they could sell quickly and see as he dust settles of reentering (which I suspect will happen for those quick on the sell trigger above $.09).
But I really think people should consider that these Advisory Board members would have an NDA in place and were not signing on if they knew this company was just going to do a RS and dilute to the cows come home.
As for the IR, I have not spoken with him because usually they CANNOT share non-public information.
Again, I have been in a company who notified shareholders of a possibility of a RS but when it finally was declared, the split was not as big as initially as expected--and the stock was on NASDAQ with a partner who funded the clinical trials.
GLTU
It is disconcerting that when people who profess to be very experienced in investing and all the ins and outs repeat falsehoods that were addressed before continue to bring them up as truths later.
"And #2 was the gifting of shares that they gave themselves this past spring. That really rubbed me the wrong way and still does."
These shares were not a GIFT, 3F. Show me where I m wrong here. Links to filings etc. Not trying to argue--just want to clarify here what you are saying to prove the accuracy of your comment. You are clearly respected on this board and your opinion carries more weight than some who complain the company is not wasting money on office rent.
I have checked this out and they were shares that came from a series of Preferred that were PURCHASED from the prior CTYX management that were converted (legally) into common stock. Now--you may consider it a "gift" that they did not have to pay much for the Preferred, but they were not gifts.
When they took control of a non-operating shell that, as anyone who has check into older filings and news from the past, was just sitting there with no business plan and no active employees, there was little value to the shell because there was NO business. They created value and they cannot cash in for that increase in value (like you have since you like CTYX, no CUBT at $.007).
By my seat here, they have formulated a plan to obtain a worlld \wide patent from the NIH, an agreement with MidAtlantic (MABT) for two other applications, and, what I consider the most promising, rights to the metformin application for the treatment of macular degeneration.
Various veterans in the biotech field are involved for a modest amount of RESTRICTED shares to advance their plan--which is unfolding.
Holding a core position and selling high volume spikes for a portion of the position have served me well. And, until I see something clearly wrong here, I will take advantage of the swings.